Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Lancet

• Publication date

  2001-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(01)06356-5PMID 11675067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C virus resistance to antiviral therapy

  2000cited by this paper
• Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon.

  2000cited by this paper
• Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

  1999cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper

• Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon‐free direct‐acting antiviral combinations?

  2018cites this paper
• Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders

  2015cites this paper
• Hepatitis C virus resistance to interferon therapy: an alarming situation

  2014cites this paper
• Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.

  2013cites this paper
• Chronic HCV and HIV Coinfection

  2012cites this paper
• Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

  2012cites this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cites this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cites this paper
• Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy

  2011cites this paper
• Hepatitis C treatment response kinetics and impact of baseline predictors

  2011cites this paper
• Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.

  2010cites this paper
• Ribavirin improves early responses to peginterferon through improved interferon signaling.

  2010cites this paper
• apid prediction of sustained virological response in patients chronically infected ith HCV by evaluation of RNA decay 48 h after the start of treatment with egylated interferon and ribavirin

  2010cites this paper
• hepatitis C Tailoring the length of antiviral treatment for

  2010cites this paper
• An early viral response to standard interferon‐alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1

  2010cites this paper
• Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.

  2010cites this paper
• Predicting the response to 48‐week combination therapy with peginterferon α‐2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients

  2009cites this paper
• Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.

  2009cites this paper
• Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load

  2009cites this paper
• Early prediction of sustained virological response at day 3 of treatment with albinterferon‐α‐2b in patients with genotype 2/3 chronic hepatitis C

  2009cites this paper
• What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?

  2009cites this paper
• Tailoring the length of antiviral treatment for hepatitis C

  2009cites this paper
• Hepatitis C viral kinetics in special populations

  2008cites this paper
• Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.

  2008influential citation
• Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co‐infection

  2008cites this paper
• Ribavirin priming in patients with chronic hepatitis C and normal ALT: a pilot study.

  2008cites this paper
• IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection

  2008cites this paper
• Towards optimal treatment for chronic hepatitis C infection

  2008cites this paper
• HOST GENETIC VARIANTS, TREATMENT OUTCOMES AND METABOLIC COMPLICATIONS IN HEPATITIS C VIRUS GENOTYPE-1

  2008cites this paper
• Very Early Viral Kinetics on Interferon Treatment in Chronic Hepatitis C virus Genotype 4 Infection

  2008cites this paper
• Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection

  2007cites this paper
• Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

  2007cites this paper
• Hepatitis B und C: Viruskinetik zur Steuerung der Therapiedauer

  2007cites this paper
• Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection

  2007cites this paper
• Safety and efficacy of an induction dose of pegylated interferon alpha‐2a on early hepatitis C virus kinetics in HIV/HCV co‐infected patients: the CORAL‐1 multicentre pilot study

  2007cites this paper
• Effect of combination therapy with ribavirin and high‐dose interferon‐α2b for 24 weeks in chronic hepatitis C

  2006cites this paper
• Aplicabilidad de la cinética del virus de la hepatitis C en el paciente coinfectado por el virus de la inmunodeficiencia humana

  2006cites this paper
• Long‐term follow‐up of chronic hepatitis C patients with sustained virological response to various forms of interferon‐based anti‐viral therapy

  2006cites this paper
• Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: Implications for clinical management of patients with chronic hepatitis C virus infection

  2006cites this paper
• [Applicability of hepatitis C virus kinetics in patients co-infected with HIV].

  2006cites this paper
• Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

  2006influential citation
• Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon-α plus Ribavirin Combination Therapy

  2006cites this paper
• Twenty‐four hour kinetics of hepatitis C virus and antiviral effect of alpha‐interferon

  2006influential citation
• Chronische Hepatitis C - Aktuelle Entwicklungen seit dem Österreichischen Therapiekonsensus 2005: Die maßgeschneiderte Therapie

  2006cites this paper
• Sustained remission of chronic hepatitis C after acute hepatitis B superinfection

  2006cites this paper
• Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.

  2006cites this paper
• First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.

  2006cites this paper
• Individualization of antiviral treatment regimens for chronic hepatitis C

  2006cites this paper
• Second thoughts about secondary analyses.

  2005cites this paper
• Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection

  2005cites this paper
• Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients.

  2005cites this paper
• Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon‐alpha 2a and ribavirin according to virological response

  2005cites this paper
• Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load

  2005cites this paper
• Benefit of Hepatitis C Virus Core Antigen Assay in Prediction of Therapeutic Response to Interferon and Ribavirin Combination Therapy

  2005cites this paper
• A real-time Taqman method for hepatitis C virus genotyping.

  2005cites this paper
• Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.

  2005cites this paper
• Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial

  2004cites this paper
• Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.

  2004cites this paper
• Current Treatment for chronic hepatitis C

  2004cites this paper
• Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.

  2004cites this paper
• Predictors of response to therapy for chronic hepatitis C.

  2004cites this paper
• Hepatitis C virus kinetics during antiviral treatment

  2004cites this paper
• Treatment of Chronic Hepatitis C: the Benelux Studies

  2004cites this paper
• Predictors of Response to Therapy for Chronic Hepatitis C

  2004cites this paper
• Recent developments in target identification against hepatitis C virus

  2004cites this paper
• Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection *

  2003cites this paper
• Development of a hepatitis C virus vaccine.

  2003cites this paper
• Impact of high‐dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy

  2003cites this paper
• Twice‐weekly administration of peginterferon‐α‐2b improves viral kinetics in patients with chronic hepatitis C genotype 1

  2003cites this paper
• Interferon-α2b Induction Treatment with or Without Ribavirin in Chronic Hepatitis C: A Multicenter, Randomized, Controlled Trial

  2003cites this paper
• Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin

  2003cites this paper
• Management of hepatitis C.

  2003cites this paper
• Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha.

  2003cites this paper
• Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?

  2003cites this paper
• Hepatitis C Virus RNA Levels During Initial Induction or Standard Interferon Therapy: Influence of Continued Treatment on Sustained Response

  2003cites this paper
• Coinfection by HIV and hepatitis A , B and C virus in adult patients . Review and GESIDA / PNS recommendations Working group for the elaboration of recommendations on viral hepatitis in HIV-infected patients

  2003cites this paper
• Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.

  2003cites this paper
• Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

  2003cites this paper
• Viral Kinetics in Hepatitis C Virus: Special Patient Populations

  2003cites this paper
• Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

  2003cites this paper
• Mathematical modeling of viral kinetics: a tool to understand and optimize therapy.

  2003cites this paper
• Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C

  2002cites this paper
• Viral kinetics of hepatitis C: New insights and remaining limitations

  2002cites this paper
• Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high‐dose interferon induction

  2002cites this paper
• Hepatobiliary scintigraphy as the diagnostic test for sphincter of Oddi dysfunction: pan the scan?

  2002cites this paper
• LETTER TO THE EDITOR Authors’ reply: first-phase parameters in hepatitis C viral kinetics

  2002cites this paper
• Cellular immune responses against hepatitis C virus: the evidence base 2002

  2002cites this paper
• Resolution of collagenous colitis after treatment for helicobacter pylori

  2002cites this paper
• Hepatitis C viral dynamics: basic concept and clinical significance.

  2002cites this paper
• Viral Kinetics and Treatment Response in Patients with Hepatitis C During Induction and Standard Interferon Therapy in Combination with Ribavirin

  2002cites this paper
• Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

  2002cites this paper
• Liver biopsy: who should do it … and who will show up in court?

  2002cites this paper
• Monitoring of viral levels during therapy of hepatitis C

  2002cites this paper
• 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients

  2002cites this paper
• Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily

  2002cites this paper
• First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

  2002cites this paper
• [Evaluation of response to treatment in chronic hepatitis C].

  2002cites this paper
• Primary interferon resistance and treatment response in chronic hepatitis C infection.

  2002cites this paper
• Coinfection with Hepatitis Viruses and HIV: Good and Bad News

  2001cites this paper
• Combination of interferon induction therapy and ribavirin in chronic hepatitis C

  2001cites this paper